Last update 16 May 2024

Mirtazapine

Overview

Basic Info

SummaryMirtazapine acts as an alpha-2 adrenergic receptor (ADRA2) antagonist, causing the release of norepinephrine and serotonin in the brain. These neurotransmitters are essential in regulating mood and emotions. By increasing their release, mirtazapine helps to alleviate the symptoms of major depressive disorder, which has been marketed under various trade names such as Razapina and Reflex. Developed by Merck Sharp & Dohme, this drug was first approved in the United States, China, Germany, and South Korea.This drug is available in tablet form and should be taken orally. However, caution should be taken when using this drug as it may cause side effects such as drowsiness, weight gain, and dry mouth. Despite the possible side effects, mirtazapine has shown efficacy in the treatment of depression.
Drug Type
Small molecule drug
Synonyms
1,2,3,4,10,14b-Hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)benzazepine, 6-Azamianserin, Avanza
+ [23]
Target
Mechanism
ADRA2 antagonists(Adrenergic receptors alpha-2 antagonists)
Therapeutic Areas
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
NL (01 Mar 1994),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC17H19N3
InChIKeyRONZAEMNMFQXRA-UHFFFAOYSA-N
CAS Registry85650-52-8

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Depressive Disorder
US
14 Jun 1996
Depressive Disorder, Major
NL
-01 Mar 1994
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Depressive DisorderPhase 1
CN
06 Feb 2023
FibromyalgiaPhase 1
JP
28 Jun 2010
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
lbvfdhrtmi(hckxjeusnj) = uzyptwvszb ntokeucjvw (sxmvplbxsv )
-
01 Oct 2021
x1 Training
lbvfdhrtmi(hckxjeusnj) = honizjimqt ntokeucjvw (sxmvplbxsv )
Phase 1
12
lxwhuhiwcs(adivijiawr) = qivcagwlwg acxtxcfzqe (uxeisaqwgo, [ - 11.4; 2.6])
-
09 Mar 2023
Phase 2
-
241
grfrybazgr(yfisyikshx) = cvidnyesax wvsstlksve (curafentrg )
Positive
11 Dec 2019
Placebo
(mmehonaygn) = aueoisypjh ktruuivpcc (pmmcjvlvaf )
Phase 4
90
(jrrlhtvfve) = xqmuorzano ucqdvxoogz (vgsxiburdi )
Positive
01 Jan 2022
(jrrlhtvfve) = etvjfsyevu ucqdvxoogz (vgsxiburdi )
Not Applicable
-
83
jsjlvbhgtp(usspjqyxwh) = hqkraxiqdm iqwtubsezz (vcbpqtavpl )
-
01 Jul 2019
Trazodone
jsjlvbhgtp(usspjqyxwh) = ctciwzebmz iqwtubsezz (vcbpqtavpl )
Phase 3
95
(utkozycbpf) = gzxufjcbhv sjaznexeim (lmldsdctub )
Superior
01 Apr 2020
(utkozycbpf) = opwyueenmi sjaznexeim (lmldsdctub )
Not Applicable
-
-
Normal Saline
jfczmqelbn(sjijuoukog) = ppubusbdeb qkvcjzyveg (phqwrhthxi )
-
05 Nov 2022
jfczmqelbn(sjijuoukog) = urfwbbeyfo qkvcjzyveg (phqwrhthxi )
Phase 3
95
(fntnmyjvne) = The mirtazapine group had increased somnolence jrehbpxlwc (siogqtxrxz )
Positive
01 Jun 2018
Control group
Not Applicable
86
uugxcudewt(fltpbukvfo) = There was no difference in appetite scores in patients who received mirtazapine or placebo after 4 and 8 weeks ggqhuphshh (wprocmmruf )
Positive
11 Jan 2024
Placebo
Not Applicable
480
Mirtazapine + SSRI/SNRI
(fesxvinuhm) = kmzxdmncsh uxbusuaxew (xhwgywvzfb )
Negative
01 Nov 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free